Michael Lobritz, MD, PhD

💡 Valuable input to the ongoing discussion on equitable access to medicines: Roche CEO Thomas Schinecker highlighted that it would be “very easy” to cut US drug prices by 50%—by removing intermediaries and enabling direct-to-patient distribution. According to Schinecker, half of supply chain earnings currently go to middlemen who take “zero risk” in the innovation process. This dialogue underscores a key challenge: ensuring broad access to life-saving therapies while preserving the necessary incentives for those who invest heavily and take the scientific and financial risks to innovate for patients in need. HealthcarePolicy #PharmaInnovation #DrugPricing #AccessToMedicine #Biopharma

83

8 Kommentare

Just finished reading the "𝘙𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘣𝘭𝘦 𝘋𝘪𝘨𝘪𝘵𝘢𝘭 𝘏𝘦𝘢𝘭𝘵𝘩 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘙𝘰𝘢𝘥𝘮𝘢𝘱" and it's a game-changer for anyone in the Swiss healthcare sector. This report isn't just about what's next in tech, it's about building a human-centered, ethical, and sustainable future for digital health. The key messages that resonated most with me are: ▪️ 𝗔𝗴𝗶𝗹𝗲 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻: We need to move beyond slow, rigid rules to a flexible framework that can keep pace with AI and other fast-moving innovations. ▪️𝗜𝗻𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗖𝗼-𝗰𝗿𝗲𝗮𝘁𝗶𝗼𝗻: It's not just about what we build, but who we build it with. True progress comes from involving everyone—from patients to policymakers—from day one. ▪️𝗩𝗮𝗹𝘂𝗲-𝗗𝗿𝗶𝘃𝗲𝗻 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: Let's focus our efforts on innovations that truly matter, those that improve patient care and address real societal needs, not just a profit motive. ▪️𝗖𝗮𝗽𝗮𝗰𝗶𝘁𝘆 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴: The future of digital health depends on equipping every stakeholder with the knowledge and skills to navigate this complex landscape responsibly. This is a must-read for policymakers and decision-makers. It’s a powerful call to action for a smarter, more collaborative approach to digital health.

145

4 Kommentare

What does patient safety actually mean? After our Patient Safety Day Daiichi Sankyo Europe GmbH, I am more convinced than ever: it is about seeing the whole person, not just the treatment. We were privileged to hear directly from Diana Dragu and Katharina Bauer about the realities shaping their lives during treatment – from fertility and lactation, to the safety of their families at home, to the need for honest conversations about future plans. These are not “side topics” – they are central to patient safety. Pharmacovigilance helps us capture these lived experiences and turn them into knowledge we can act on. Listening alone is not enough. It is our responsibility to ensure these insights lead to tangible changes – in how we design our studies, how we counsel patients, and how we make sure our approach to treatment considers real-world needs. I cannot emphasize enough that patient safety is truly a shared mission. From Medical Affairs to Pharmacovigilance, from clinical teams to affiliates, each of us plays an important role in making sure treatments are not only effective but also safe and supportive. To patients and families – what aspects of safety matter most to you during and after treatment? 

156

10 Kommentare

Proud to put the spotlight on our Genomic Medicine Unit’s pioneering work in this new Sanofi.com article. The piece explores the exciting potential of #genetherapy to expand beyond the rare, monogenic disorders where it has traditionally been applied to use in immune-mediated diseases such as macular degeneration. To do so, one of the biggest challenges we face is making sure treatments reach exactly the right cells in the right places to avoid the body’s natural immune defenses—an exercise in the ultimate precision engineering. We’re using AI to engineer new viral vectors that can bypass pre-existing immunity and making progress in developing non-viral, therapies using lipid nanoparticles loaded with #mRNA.   This science is bringing us closer to more precision therapies, and it is thanks to the exceptional talent and collaborative spirit of the GMU team. Together, we are working toward a future where we could potentially offer patients a single treatment that could change their disease—and their lives.   Read the full article to see how we're building the future of genomic medicine:  http://spkl.io/6044AGQcI

380

15 Kommentare